Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Melanoma × fluoromisonidazole × Clear all

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Conditions

Head and Neck Neoplasms 4 Glioblastoma 4 Brain Neoplasms 4 Squamous Cell Carcinoma of Head and Neck 3 Lung Neoplasms 3 Glioma 3 Carcinoma, Non-Small-Cell Lung 3 Carcinoma, Hepatocellular 3 Small Cell Lung Carcinoma 2 Sarcoma 2 Liver Neoplasms 2 Breast Neoplasms 2 Uterine Cervical Neoplasms 1 Unspecified Adult Solid Tumor, Protocol Specific 1 Triple Negative Breast Neoplasms 1 Tongue Neoplasms 1 Stage III Lung Non-Small Cell Cancer AJCC v7 1 Skin Neoplasms 1 Salivary Gland Neoplasms 1 Rectal Neoplasms 1 Oropharyngeal Neoplasms 1 Neoplasms 1 Neoplasm Metastasis 1 Nasopharyngeal Neoplasms 1 Mouth Neoplasms 1 Meningioma 1 Melanoma 1 Laryngeal Neoplasms 1 Hypoxia 1 Hypopharyngeal Neoplasms 1

Interventions

pembrolizumab 268 Nivolumab 241 Ipilimumab 221 aldesleukin 126 Cyclophosphamide 126 Interleukin-2 93 trametinib 76 dabrafenib 68 Dacarbazine 68 Temozolomide 66 fludarabine 64 Vemurafenib 64 fludarabine phosphate 56 Biopsy 45 Radiosurgery 43 sargramostim 40 Bevacizumab 40 binimetinib 39 incomplete Freund's adjuvant 37 Paclitaxel 35 atezolizumab 34 Radiotherapy 34 Cisplatin 34 Blood Specimen Collection 33 encorafenib 32 Magnetic Resonance Spectroscopy 32 cobimetinib 31 Specimen Handling 31 Introns 31 Carboplatin 29

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT02061007 2016-05-09

Biomarker Correlates of Hypoxia in Metastatic Melanoma

H. Lee Moffitt Cancer Center and Research Institute

Phase 2 Withdrawn

Melanoma, Skin Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon ⚡